News

Personalization declared route to improved AF care


 

FROM EUROPACE

This statement will be presented on Sept. 3 in a session on personalized medicine at the annual congress of the European Society of Cardiology in Amsterdam.

Dr. Kirchhof said that he has received consulting fees or honoraria from 16 different drug companies and device manufacturers. His complete disclosure statement as well as disclosures from the other task force members are listed in the statement document.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

Good news for apixaban in recurrent VTE prevention
MDedge Neurology
FDA makes dabigatran contraindicated for mechanical valves
MDedge Neurology
FDA approves apixaban for nonvalvular atrial fibrillation population
MDedge Neurology
PFOs raise stroke risk from ICDs, pacemakers
MDedge Neurology
VIDEO: Marijuana may raise stroke risk
MDedge Neurology
PFOs raise stroke risk from devices
MDedge Neurology
Apixaban, dabigatran found effective, safe for extended post-VTE therapy
MDedge Neurology
Watchman device hits home run in PROTECT AF trial
MDedge Neurology
New risk scheme to predict stroke in AF
MDedge Neurology
Fingolimod heart effects usually resolve within 6 hours
MDedge Neurology